Wockhardt Overview
- Status
-
Public
- Employees
-
3,143
- Stock Symbol
-
532300
- Investments
-
5
- Share Price
-
$4.06
- (As of Friday Closing)
Wockhardt General Information
Description
Wockhardt Ltd is a major drug manufacturing company with a focus on pharmaceutical and biotechnology products. The company conducts research in the fields of pharmaceuticals and biotechnology while also operating its chain of Super Specialty Hospitals. The vast majority of the company's revenue is generated in Europe. The company also operates in China, Japan, and Russia. The company's strategy includes the use of acquisitions, strategic partnerships, and contract manufacturing.
Contact Information
- Wockhardt Towers
- Bandra Kurla Complex, Bandra (East)
- Mumbai, 400051
- India
Wockhardt Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.06 | $4.11 | $1.77 - $4.18 | $585M | 144M | 140K | -$0.43 |
Wockhardt Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 |
|---|---|---|---|---|
| EV | 699,958 | 550,004 | 882,086 | 846,681 |
| Revenue | 336,524 | 329,523 | 430,829 | 362,769 |
| EBITDA | 11,303 | (10,710) | 15,032 | (13,441) |
| Net Income | (101,358) | (69,616) | (32,748) | 92,204 |
| Total Assets | 891,741 | 935,799 | 1,087,061 | 1,058,468 |
| Total Debt | 273,291 | 266,014 | 289,865 | 364,078 |
Wockhardt Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Wockhardt Comparisons
Industry
Financing
Details
000000
00000
Wockhardt Competitors (26)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Strides Pharma Science | Corporation | Bangalore, India | 0000 | 000.00 | 000000000 | 000.00 |
| 00000 | Corporation | Basel, Switzerland | 000000 | 000.00 | 000000000000 | 000.00 |
| 000000000 000000 | Corporation | Hyderabad, India | 00000 | 00000 | 000000000 | 00000 |
| 0000 0000000000000 | Corporation | Mississauga, Canada | 00 | |||
| 000000 | Formerly PE-Backed | Bengaluru, India | 00000 | 000.00 | 00000000 | 000.00 |
Wockhardt Patents
Wockhardt Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4061331-A1 | Oral film composition comprising levothyroxine | Inactive | 22-Nov-2019 | 000000000 | |
| US-20230338320-A1 | Oral film composition comprising levothyroxine | Pending | 22-Nov-2019 | 0000000000 | |
| AU-2020366731-A1 | Nitrogen containing bicyclic compounds | Pending | 18-Oct-2019 | 0000000000 | |
| CA-3158337-A1 | Nitrogen containing bicyclic compounds | Pending | 18-Oct-2019 | 0000000000 | |
| EP-4045040-A1 | Nitrogen containing bicyclic compounds | Active | 18-Oct-2019 | A61K31/439 |
Wockhardt Executive Team (10)
Wockhardt Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000000 00000 | Self | Board Member | 000 0000 |
| 0000 00000 | Self | Independent Director | 000 0000 |
| 00000000 0000 | Self | Board Member | 000 0000 |
| 00000 00000000000 | Wockhardt | Chairman & Board Member | 000 0000 |
| 0000000 0000000000 | Wockhardt | Board Member & Managing Director | 000 0000 |
Wockhardt Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Wockhardt Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Laboratoires Negma | 10-Nov-2007 | 0000000000 | 00000 | Pharmaceuticals | 00000 000 |
| Morton Grove Pharmaceuticals | 23-Oct-2007 | 0000000000 | 0000 | Drug Delivery | |
| Pinewood Healthcare | 03-Oct-2007 | 0000000000 | 00000 | Pharmaceuticals | 00000 000 |
| Esparma | 06-May-2004 | 0000000000 | 0000 | Pharmaceuticals | |
| CP Pharmaceuticals | 15-Jul-2003 | Merger/Acquisition | 0000 | Pharmaceuticals | 00000 000 |
Wockhardt Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Pinewood Healthcare | Pharmaceuticals | Clonmel, Ireland | 0000 |
Wockhardt ESG
Risk Overview
Risk Rating
Updated April, 20, 2023
40.64 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 418
Rank
Percentile
Wockhardt Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Esparma | 06-May-2004 | 000000000000000000 | 0000 | Completed |
|